Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to... see more

TSXV:BTI - Post Discussion

View:
Post by beenthere on Jan 24, 2023 7:29pm

Hey narmac

Hey narmac, you are one of the most positive investors here!

How about we all put our collective minds together over the next few days and will a positive response from J&J!
Comment by narmac on Jan 25, 2023 4:51am
Agreed Beenthere,,,,,is all lost?,,not by a long shot imo,,,,,those who are not wishing to have input into their investment have that right to do so. Why blame anyone else for their lack of response. If you dont want to discuss possibilities and make calls and get involved you probably dont use proxyvote and dont intend to,,,or have never provided input before. I would like to see DrDR step down ...more  
Comment by prophetoffactz on Jan 25, 2023 9:25am
"We need a CEO with a vision, connections and negotiating skills." Sounds like Rathjen. She had the connections to Ladenberg Thalmann and got the ball rolling. Her vision was as big as getting the Former Finance Director of Shire Pharmaceuticals to run the company. He defied anyone to find a company of Biodexa's size with more opportunity. It would no longer be just dependent on ...more  
Comment by narmac on Jan 25, 2023 9:36am
Stamp couldnt sell the arrangement to his shareholders!!!!!,,,,,seems both companies felt they were getting the shaft,,,and we are not in mining!,,if the deal was less a win lose for all participants then original shareholders might have swalled the bait,,but nope,,,greed fouled the financiers attempt to master mind full control of these companies.
Comment by narmac on Jan 25, 2023 9:39am
,,They could finance Bioasis with a 25-75 arrangement and we can sell a license to Midatech,,,,,isnt that the business model we have??,,,,why did DrDR want others to perform her assigned duties ??? Hummmmm,,, I wonder!!!
Comment by prophetoffactz on Jan 25, 2023 9:46am
Stamp was dealing with a shareholder base that doesn't even tune in. Only 35.6% of the shareholder base even voted. With ~62.5% of the vote for various resolutions he almost got it done despite the absent shareholder base It didn't take many worked up into a frenzy about the share count with no appreciation of the asset base to throw the vote. It reads more lke a market failure than a ...more  
Comment by OttawaPeter on Jan 25, 2023 11:02am
  LOL - oh my goodness (wipes away tears) - you are quite the comedian- seriously, what an absolute joke! DR is none of those things & can really NOT be credited for Chiesi or J&J-Nor should she get credit for failed deals that aren't even happening. We all know you're a paid shill, an an ineffective one at that. 
Comment by narmac on Jan 25, 2023 5:00am
On a side note,,,,,,remember Stephen Stamp CEO of Midatech holds a finance degree. He does not have a background in the bio sciences. He brings a banker type ability to the table. This maybe more important then it seesm. We could also bring a business type person in as afull time or temp CEO. As Dr. Mei Mei holds the bioscinece background needed going forward. Just a point of interest.
Comment by Boomskid on Jan 25, 2023 7:45am
It's been a question raised for years about the odds of hiring a scientist as CEO who is also a good manager, financier, strategic thinker, and entrepreneur. (Dr. Ryan Watts, CEO of Denali makes the case that they exist, but he already has a job.)  There is a persistent notion that any person smart enough to acquire a PhD must surely be smart enough to be a corporate leader. I have ...more  
Comment by zwerp2000 on Jan 25, 2023 8:15am
But again, there are debt obligations coming due very soon. The company can't pay them, The company can't raise any significant funds to pay them or continue operations. The company had years to address this and failed to do so. My belief is that xb3 is junk and worthless which is the real reason but either way, the company does not have the means to do anything. The company did absolutely ...more  
Comment by Boomskid on Jan 25, 2023 8:40am
All of that could be true, zwerp2000. But why did LT and The Placee want 75% of Biodexa? Why did they spend a year trying to make that happen?  It wasn't Cresence's EGF. They were involved in that. They could have outbid Bioasis out of petty cash. Was it Midatech that they wanted? Then why bring Bioasis into the deal? I suppose that bringing Bioasis in could be thought of in the ...more  
Comment by zwerp2000 on Jan 25, 2023 9:22am
But does it matter whether LT is really pursuing BTI? At this point, BTI has no money, no real ability to raise money and debt obligations that are coming due soon. I do not believe there is any value in their platform and i think the market has been telling you that for years. But that, imo, may not even matter. I am no sure how this company continues to operate over the next few months. I don ...more  
Comment by prophetoffactz on Jan 25, 2023 8:48am
Midatech hires former Shire finance director Stephen Stamp as CFO Stamp was FD at both Shire and Regus when they completed their initial public offers on the London Stock Exchange, as well as overseeing a number of major acquisitions and financings   Midatech Pharma PLC (LON:MTPH) has appointed former Shire Pharmaceuticals finance director Stephen Stamp as its new chief ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities